Alaunos Therapeutics Inc (TCRT) - Total Liabilities
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has total liabilities worth $813.00K USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Alaunos Therapeutics Inc to assess how effectively this company generates cash.
Alaunos Therapeutics Inc - Total Liabilities Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Alaunos Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Alaunos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Alaunos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Munic SA
PA:ALMUN
|
France | €8.67 Million |
|
Warehouse REIT plc
LSE:WHR
|
UK | GBX300.12 Million |
|
Gayatri Highways Limited
NSE:GAYAHWS
|
India | Rs16.12 Billion |
|
Betacom S.A.
WAR:BCM
|
Poland | zł36.15 Million |
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
USA | $1.79 Million |
|
Gentrogroup Co. Ltd.
KQ:083660
|
Korea | ₩22.28 Billion |
|
mTouche Technology Bhd
KLSE:0092
|
Malaysia | RM17.10 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Alaunos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TCRT stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alaunos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual total liabilities of Alaunos Therapeutics Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $813.00K | +17.49% |
| 2024-12-31 | $692.00K | -64.62% |
| 2023-12-31 | $1.96 Million | -92.59% |
| 2022-12-31 | $26.38 Million | -28.33% |
| 2021-12-31 | $36.81 Million | +64.59% |
| 2020-12-31 | $22.36 Million | +58.56% |
| 2019-12-31 | $14.10 Million | +48.67% |
| 2018-12-31 | $9.49 Million | -95.31% |
| 2017-12-31 | $202.41 Million | +10.22% |
| 2016-12-31 | $183.65 Million | +176.77% |
| 2015-12-31 | $66.35 Million | +482.25% |
| 2014-12-31 | $11.40 Million | -49.06% |
| 2013-12-31 | $22.37 Million | -36.01% |
| 2012-12-31 | $34.96 Million | -4.22% |
| 2011-12-31 | $36.50 Million | +17.87% |
| 2010-12-31 | $30.97 Million | +43.15% |
| 2009-12-31 | $21.63 Million | +270.79% |
| 2008-12-31 | $5.83 Million | -8.22% |
| 2007-12-31 | $6.36 Million | +113.37% |
| 2006-12-31 | $2.98 Million | +30.07% |
| 2005-12-31 | $2.29 Million | +10782.70% |
| 2004-12-31 | $21.05K | -18.17% |
| 2003-12-31 | $25.72K | +44.21% |
| 2002-12-31 | $17.84K | +224.27% |
| 2001-12-31 | $5.50K | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.… Read more